Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach

Bristol Myers Squibb Company’s three top-selling drugs – accounting for more than half of its 2020 revenue – will lose market exclusivity during this decade, putting pressure on the company’s R&D pipeline to generate new products. BMS recently highlighted later-stage assets that will help fill the void when generic and biosimilar competitors for Revlimid, Eliquis and Opdivo emerge in 2022, 2026 and 2027, respectively, but earlier-stage programs may offer upside beyond those future growth generators.